Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.

Fiche publication

Date publication

décembre 2024

Journal

Annals of the rheumatic diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric , Dr SEBBAG Eden

Tous les auteurs :
Sebbag E, Molina-Collada J, Ndoye R, Aletaha D, Askling J, Gente K, Bertheussen H, Bitoun S, Bolek EC, Buch MH, Burmester GR, Canhão HM, Chatzidionysiou K, Curtis JR, Danlos FX, Guimarães V, Hetland ML, Iannone F, Kostine M, Kragstrup TW, Kvien TK, Regierer AC, Schulze-Koops H, Sedmak N, Silva-Fernández L, Szekanecz Z, Lauper K, Finckh A, Gottenberg JE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39739386

Résumé

Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.